Liver Transplant trial for cholangiocarcinoma

@gerhardt26, Welcome to Connect. I have located this link to this research study. It looks like it is currently accepting participants at Mayo Arizona. Here is a link for more information:
Pilot Study to Assess the Validity of "Liquid Biopsy" to Improve Diagnosis, Prognostic Assessment and Disease Monitoring in Patients Undergoing Liver Transplant for Hilar and Intrahepatic Cholangiocarcinoma
https://www.mayo.edu/research/clinical-trials/cls-20506995
@gerhardt26, Is this the study that you had in mind?

Yes! Thank you so much. You are simply lovely!

I am assuming you are looking for a liver transplant trial for an intrahepatic cholangiocarcinoma which is currently not an indication for transplant in most centers. Liver transplant for hilar cholangiocarcinoma on the other hand is done at many centers in the country as standard and not as a trial. If my assumption is correct and you are looking for liver transplant trial for intrahepatic cholangiocarcinoma carcinoma patient, please contact Dr. William Chapman’s office at Washington University Barnes Jewish Medical Center in St. Louis or the Houston Methodist Hospital Liver Transplant team led by Dr. Mark Ghoby, Houston Texas. The RESTORE trial at Barnes Jewish is considered cutting edge and these two centers are considered more advanced than some of the better marketed but less advanced centers where there may be larger volume of transplants but for standard known indications only. Dr. Fung and his team in University of Chicago also does liver transplants for intrahepatic cholangiocarcinoma and have been doing so without a trial in the past. They may be collaborating with Houston Methodist as well. Trials have specific eligibility criteria that is center dependent. Trial patients usually receive extended criteria livers with normothermic machine perfusion. Encouraging results already seen where intrahepatic cholangiocarcinoma patients often with recurrence but now with stable disease previously treated with multiple cycle chemotherapy and / or radiation including intrahepatic radio embolization (Y-90) procedure have finally been treated successfully by this method. Only a handful centers are treating intrahepatic cholangiocarcinoma with liver transplant. The sad part is some high volume University Centers are not only behind times and not offering transplants to intrahepatic cholangiocarcinoma patients but not even informing patients of this option elsewhere simply telling patients they are not eligible for transplant based on standard transplant criteria, as they don’t offer any trials. It is difficult to give them the benefit of doubt as liver transplant surgeons are a small community and it is easy to become aware of the trials and latest treatment options. The paper presented by Dr. Mark Ghobrial’s group from Houston Methodist hospital describing their success with intrahepatic cholangiocarcinoma patients in 2018 was what spurred the trials that continue to show encouraging results.